APP antisense oligonucleotides are effective in rescuing mitochondrial phenotypes in human iPSC‐derived trisomy 21 astrocytes
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.14560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Srishruthi Thirumalai und 3 weiteren Autor:innen. Beteiligte Einrichtung: UCL Great Ormond Street Institute of Child Health, Zayed Centre for Research into Rare Disease in Children, London, UK. Hauptthemen laut MEDLINE: Astrocytes, Induced Pluripotent Stem Cells, Down Syndrome, Mitochondria. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Research UK, Alzheimer’s Research UK.
Abstract (Originalsprache)
INTRODUCTION Antisense oligonucleotides (ASOs) have shown promise in reducing amyloid precursor protein (APP) levels in neurons, but their effects in astrocytes, key contributors to neurodegenerative diseases, remain unclear. This study evaluates the efficacy of APP ASOs in astrocytes derived from an individual with Down syndrome (DS), a population at high risk for Alzheimer's disease (AD). METHODS Human induced pluripotent stem cells (hiPSCs) from a healthy individual and an individual with DS were differentiated into astrocytes. Astrocytes were treated with APP ASOs for 10 days, and APP levels were quantified. Mitochondrial morphology and superoxide production in DS astrocytes were analyzed using super‐resolution and confocal microscopy. RESULTS APP ASOs significantly reduced APP levels in astrocytes from both control and DS individuals. In DS astrocytes, treatment restored mitochondrial health, increasing mitochondrial number and size while reducing superoxide production. DISCUSSION APP ASOs effectively reduce APP levels and improve mitochondrial health in astrocytes, suggesting their potential as a therapeutic approach for DS and DS‐related AD. Further in vivo studies are required to confirm these findings. Highlights APP ASOs reduce APP levels in human iPSC‐derived astrocytes. APP ASO treatment rescues mitochondrial phenotypes in trisomy 21 astrocytes. This study supports ASOs as a potential therapy for Down syndrome‐related Alzheimer's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL Great Ormond Street Institute of Child Health, Zayed Centre for Research into Rare Disease in Children, London, UK.
- Talisman Therapeutics, Babraham Research Campus, Cambridge, UK.
- Human Stem Cells and Neurodegeneration Laboratory, The Francis Crick Institute, London, UK.
- Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, Queen Square, London, UK.
- Department of Neuroscience, City University of Hong Kong, Hong Kong, Hong Kong.
Förderung
- Alzheimer's Research UK
- Alzheimer’s Research UK
Zitieren
APA
Thirumalai, S., Livesey, F. J., Patani, R., & Hung, C. (2025). APP antisense oligonucleotides are effective in rescuing mitochondrial phenotypes in human iPSC‐derived trisomy 21 astrocytes. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14560
Vancouver
Thirumalai S, Livesey FJ, Patani R, Hung C. APP antisense oligonucleotides are effective in rescuing mitochondrial phenotypes in human iPSC‐derived trisomy 21 astrocytes. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14560
BibTeX
@article{Thirumalai2025,
author = {Thirumalai, Srishruthi and Livesey, Frederick J and Patani, Rickie and Hung, Christy},
title = {APP antisense oligonucleotides are effective in rescuing mitochondrial phenotypes in human iPSC‐derived trisomy 21 astrocytes},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.14560}
}
EUVIMED